Commentary

Teriparatide: Label changes and identifying patients for long-term use

Paul D. Miller, MD, HDSc (HON), E. Michael Lewiecki, MD, Kelly Krohn, MD and Elliott Schwartz, MD
Cleveland Clinic Journal of Medicine September 2021, 88 (9) 489-493; DOI: https://doi.org/10.3949/ccjm.88a.21011

Article Information

vol. 88 no. 9 489-493
DOI 
https://doi.org/10.3949/ccjm.88a.21011
PubMed 
34470753
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online September 1, 2021.
Copyright & Usage 
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Paul D. Miller, MD, HDSc (HON)⇑
  1. The University of Colorado Health Sciences Center; The Colorado Center for Bone Health, Lakewood, CO
  1. Address:
    Paul D. Miller, MD, HDSc (HON), Colorado Center for Bone Health, PC, 6655 W. Jewell Avenue, Suite #2, Lakewood, CO 80232; pmiller{at}millerbonecenter.com
  1. E. Michael Lewiecki, MD
  1. Director, New Mexico Clinical Research & Osteoporosis Center; Director, Bone Health TeleECHO, University of New Mexico Health Sciences Center, Albuquerque, NM
  1. Kelly Krohn, MD
  1. The University of Arizona College of Medicine, Phoenix, AZ
  1. Elliott Schwartz, MD
  1. Northern California Institute for Bone Health, Inc., Orinda, CA; Department of Orthopedics, The University of California San Francisco Skeletal Health Service, San Francisco, CA
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects